Lite Strategy (LITS) Total Liabilities (2011 - 2026)
Lite Strategy (LITS) posted quarterly Total Liabilities of $952000.0 for Q1 2026, down 23.1% year-over-year from $1.2 million in Q1 2025, and down 12.42% quarter-over-quarter from $1.1 million in Q4 2025.
Lite Strategy (LITS) Total Liabilities (2011 - 2026) Analysis & Trends
Lite Strategy's Total Liabilities history runs 16 years deep, the most recent figure standing at $952000.0 for Q1 2026.
- In Q1 2026, Total Liabilities fell 23.1% year-over-year to $952000.0; the TTM figure through Mar 2026 stood at $952000.0 (down 23.1% YoY), while the FY2025 annual figure was $1.4 million, down 83.79% from the prior year.
- Total Liabilities for Q1 2026 stood at $952000.0, down from $1.1 million in the prior quarter.
- The five-year high for Total Liabilities was $126.6 million in Q1 2022, with the low at $952000.0 in Q1 2026.
- The 5-year median for Total Liabilities is $19.0 million (2023), against an average of $44.2 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities increased 0.64% in 2022, then sank 93.88% in 2025.
- Lite Strategy's Total Liabilities stood at $99.2 million in 2022, then tumbled by 80.8% to $19.0 million in 2023, then plunged by 87.99% to $2.3 million in 2024, then tumbled by 52.47% to $1.1 million in 2025, then dropped by 12.42% to $952000.0 in 2026.
- Business Quant data shows LITS's Total Liabilities at $952000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | 952,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 952,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 8.36 Mn |
| Mar 31, 2024 | 20.23 Mn |
| Dec 31, 2023 | 19.05 Mn |
| Sep 30, 2023 | 19.89 Mn |
| Jun 30, 2023 | 96.19 Mn |
| Mar 31, 2023 | 99.83 Mn |
| Dec 31, 2022 | 99.23 Mn |
| Sep 30, 2022 | 126.28 Mn |
| Jun 30, 2022 | 125.43 Mn |
| Mar 31, 2022 | 126.62 Mn |
| Dec 31, 2021 | 136.13 Mn |
| Sep 30, 2021 | 142.05 Mn |
| Jun 30, 2021 | 124.63 Mn |